Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
08 août 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics Reports Second Quarter 2024 Financial Results
and Business Updates
Autolus Therapeutics to Present Three Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
03 nov. 2022 09h31 HE
|
Autolus Therapeutics plc
obe-cel: poster presentation in B-ALL and B-NHL patientsAUTO1/22: poster presentation in pediatric ALL patientsAUTO4: poster presentation in T-Cell Lymphoma patients LONDON, Nov. 03, 2022 ...
Autolus Therapeutics announces publication of new AUTO6 Phase 1 data in childhood neuroblastoma in Science Translational Medicine
30 nov. 2020 07h00 HE
|
Autolus Therapeutics plc
- Findings from the Phase 1 study provide evidence that AUTO6 induces clinical activity in this solid tumor setting without inducing on-target off-tumor toxicity - AUTO6NG builds on this approach...
Autolus Therapeutics presents new preclinical data during the Virtual 2020 AACR Annual Meeting
22 juin 2020 07h00 HE
|
Autolus Therapeutics plc
- AUTO5 in T cell lymphoma – new in vitro and in vivo data presented demonstrating highly selective targeting of TRBC2 by a novel CAR T candidate - AUTO6NG in small cell lung cancer – in vitro and in...
Autolus Therapeutics to Present New Data at the Virtual 2020 AACR Annual Meeting
15 mai 2020 11h20 HE
|
Autolus Therapeutics plc
- Preclinical data on AUTO5 in T cell lymphoma and solid tumor data on AUTO6NG in small cell lung cancer and AUTO7 in prostate cancer - Conference Call and Webcast to be held Thursday, June 25,...
Autolus Therapeutics Presents Preclinical Data on AUT06NG at the SITC Annual Meeting
09 nov. 2019 07h00 HE
|
Autolus Therapeutics plc
LONDON, Nov. 09, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment...